4.7 Article

New Flexible Analogues of 8-Aza-7-deazapurine Nucleosides as Potential Antibacterial Agents

期刊

出版社

MDPI
DOI: 10.3390/ijms242015421

关键词

fleximer; nucleoside analogues; antibacterial activity; inhibitor; antituberculosis activity

向作者/读者索取更多资源

A variety of flexible derivatives of 8-aza-7-deazahypoxanthine were synthesized and screened for antibacterial activity. Some of the compounds showed significant inhibition against the growth of Mycobacterium tuberculosis.
A variety of ribo-, 2 '-deoxyribo-, and 5 '-norcarbocyclic derivatives of the 8-aza-7-deazahypoxanthine fleximer scaffolds were designed, synthesized, and screened for antibacterial activity. Both chemical and chemoenzymatic methods of synthesis for the 8-aza-7-deazainosine fleximers were compared. In the case of the 8-aza-7-deazahypoxanthine fleximer, the transglycosylation reaction proceeded with the formation of side products. In the case of the protected fleximer base, 1-(4-benzyloxypyrimidin-5-yl)pyrazole, the reaction proceeded selectively with formation of only one product. However, both synthetic routes to realize the fleximer ribonucleoside (3) worked with equal efficiency. The new compounds, as well as some 8-aza-7-deazapurine nucleosides synthesized previously, were studied against Gram-positive and Gram-negative bacteria and M. tuberculosis. It was shown that 1-(beta-D-ribofuranosyl)-4-(2-aminopyridin-3-yl)pyrazole (19) and 1-(2 ',3 ',4 '-trihydroxycyclopent-1 '-yl)-4-(pyrimidin-4(3H)-on-5-yl)pyrazole (9) were able to inhibit the growth of M. smegmatis mc2 155 by 99% at concentrations (MIC99) of 50 and 13 mu g/mL, respectively. Antimycobacterial activities were revealed for 4-(4-aminopyridin-3-yl)-1H-pyrazol (10) and 1-(4 '-hydroxy-2 '-cyclopenten-1 '-yl)-4-(4-benzyloxypyrimidin-5-yl)pyrazole (6). At concentrations (MIC99) of 40 and 20 mu g/mL, respectively, the compounds resulted in 99% inhibition of M. tuberculosis growth.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据